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Background  and  aims:  Since  liver  ﬁbrosis  index  (LFI)  was  developed  by  Fujimoto  et  al.,  real-
time elastography  (RTE)  has  become  a  promising  non-invasive  technique  to  assess  ﬁbrosis  in
chronic hepatitis  C  (CHC).  The  aims  of  this  study  were  to  compare  the  diagnostic  performance
of RTE  versus  laboratory  tests  to  predict  advanced  ﬁbrosis  (METAVIR  scoring  system:  F  ≥  3)  in
patients with  CHC,  using  liver  biopsy  (LB)  as  the  reference  standard;  and  to  evaluated  the
impact of  patient  anthropometric  features  on  RTE  histogram  acquisition.
Methods:  This  prospective  study  included  37  patients  with  CHC  scheduled  for  LB.  Aspartate
aminotransferase  (AST)/alanine  aminotransferase  (AST)  ratio,  AST/platelet  ratio  index  (APRI),
and Fibrosis-4  index  (FIB-4)  were  calculated  from  recent  (≤6  months)  laboratory  data.  RTE  was
performed  by  two  independent  operators  blind  to  each  other’  ﬁndings  and  to  LB  results,  using
Hitachi HI-VISION  Avius  ultrasound  system.  According  to  Hitachi  RTE  software,  liver  elasticity
was evaluated  through  the  LFI.  Percutaneous  ultrasound-assisted  LB  was  performed  in  the  same
day of  RTE.  All  LB  specimens  were  analyzed  by  an  expert  pathologist  blind  to  RTE  results.  Hepatic
ﬁbrosis was  staged  according  to  METAVIR  scoring  system.  The  diagnostic  performance  of  the  LFI,
AST/ALT ratio,  APRI  and  FIB-4  for  predicting  advanced  ﬁbrosis  was  assessed  using  area  under
receiver-operating  characteristic  curve  (AUROC),  sensitivity,  speciﬁcity,  positive-predictive  and
negative-predictive  (NPV)  values.
Results:  Thirty-seven  LB  were  performed  without  complications.  The  distribution  according  to
METAVIR scoring  system  was  F0--1  in  13  patients  (35%),  F2  in  13  (35%),  F3  in  9  (25%)  and  F4
in 2  (5%).  Thirty-seven  RTE  procedures  were  performed.  Histogram  acquisition  was  success-ts  (86%).  Abdominal  wall  thickness  ≥23  mm  was  associated  with  no
.018).  Using  the  optimal  cut-off  value  of  2.38,  the  AUROC  for  the
for  the  AST/ALT  ratio,  APRI  and  FIB-4  were  0.62,  0.79,  and  0.82,fully achieved  in  32  patien
histogram  acquisition  (p  =  0
LFI was  0.73.  The  AUROC  
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Conclusions:  The  LFI  calculated  by  RTE  showed  a  very  good  diagnostic  performance  to  predict
advanced ﬁbrosis  in  CHC,  with  remarkable  sensitivity  and  NPV  (both  100%).
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Resumo
Introduc¸ão  e  Objetivos:  Após  o  desenvolvimento  do  liver  ﬁbrosis  index  (LFI)  por  Fujimoto
K. et  al.,  a  elastograﬁa  em  tempo  real  tornou-se  uma  técnica  não  invasiva  promissora  na
avaliac¸ão do  grau  de  ﬁbrose  na  hepatite  C  crónica.  Os  objetivos  deste  estudo  foram  com-
parar a  acuidade  diagnóstica  da  elastograﬁa  em  tempo  real  com  a  de  testes  laboratoriais  para
predizer  ﬁbrose  avanc¸ada  (sistema  de  estadiamento  METAVIR:  F≥3)  em  doentes  com  hepatite  C
crónica, utilizando  a  biópsia  hepática  como  goldstandard;  e  avaliar  o  impacto  das  características
antropométricas  do  doente  na  aquisic¸ão  de  histograma.
Métodos:  Este  estudo  prospetivo  incluiu  37  doentes  com  hepatite  C  crónica  referenciados  para
biópsia hepática.  A  razão  aspartato  aminotransferase  (AST)/alanina  aminotransferase  (AST)
(AST/ALT  ratio),  o  índice  da  razão  AST/plaquetas  (APRI)  e  o  índice  Fibrosis-4  (FIB-4)  foram  cal-
culados a  partir  de  dados  laboratoriais  recentes  (≤6  meses).  O  procedimento  de  elastograﬁa  em
tempo real  foi  realizado  por  dois  operadores  independentes,  cegos  entre  si  e  para  o  resultado
da biópsia  hepática,  utilizando  o  ecógrafo  Hitachi  HI-VISION  Avius.  De  acordo  com  o  software
de elastograﬁa  em  tempo  real  da  Hitachi,  a  elasticidade  hepática  foi  avaliada  através  do  LFI.
No mesmo  dia  da  elastograﬁa  em  tempo  real,  realizou-se  biópsia  hepática  percutânea  após
marcac¸ão ecográﬁca  do  local  de  punc¸ão.  Todas  as  biópsias  hepáticas  foram  analisadas  por
um anatomopatologista  cego  para  o  resultado  da  elastograﬁa  em  tempo  real.  Para  estadia-
mento da  ﬁbrose  hepática  foi  utilizada  a  classiﬁcac¸ão  METAVIR.  A  acuidade  diagnóstica  do  LFI,
AST/ALT  ratio,  APRI  e  FIB-4  para  predizer  ﬁbrose  avanc¸ada  foi  avaliada  com  base  nos  valores
da área  abaixo  curva  recebedora  das  características  dos  operadores  (AUROC),  sensibilidade,
especiﬁcidade  e  valores  preditivos  positivo  e  negativo.
Resultados:  Foram  realizadas  37  biópsias  hepáticas,  sem  complicac¸ões.  A  distribuic¸ão  segundo
o sistema  de  estadiamento  METAVIR  foi  F0-1  em  13  doentes  (35%),  F2  em  13  (35%),  F3  em  9  (25%)
e F4  em  2  (5%).  Foram  realizados  37  procedimentos  de  elastograﬁa  em  tempo  real.  A  aquisic¸ão
de histograma  foi  conseguida  em  32  doentes  (86%).  A  espessura  da  parede  abdominal  ≥23  mm
foi um  factor  independente  associado  a  não  aquisic¸ão  de  histograma  (p  =  0,018).  Utilizando  o
cut-off óptimo  de  2,38,  o  valor  da  AUROC  para  o  LFI  foi  0,73.  Os  valores  da  AUROC  para  o
AST/ALT ratio,  APRI  e  FIB-4  foram  0,62,  0,79  e  0,82,  respectivamente.
Conclusões:  O  LFI  determinado  por  elastograﬁa  em  tempo  real  demonstrou  uma  performance
diagnóstica  muito  boa  para  predizer  ﬁbrose  avanc¸ada  (F≥3)  na  hepatite  C  crónica,  com  sensi-
bilidade e  valor  preditivo  negativo  excepcionais  (ambos  100%).
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.



















n  patients  with  chronic  hepatitis  C  (CHC),  prognosis,  surveil-
ance  and  treatment  management  are  driven  largely  by
he  extent  of  ﬁbrosis.1,2 Percutaneous  liver  biopsy  (LB)  has
een  traditionally  considered  the  gold  standard  method  for
he  assessment  of  liver  ﬁbrosis  in  CHC.3 However,  it  is  an
nvasive  and  costly  procedure  associated  with  patient  dis-
omfort  and,  in  rare  instances,  with  serious  complications.4
oreover,  LB  accuracy  is  limited  by  sampling  errors  and  sig-




en  the  past  few  years,  research  has  been  focused  on  the
evelopment  and  evaluation  of  non-invasive  methods  for  the
ssessment  of  liver  ﬁbrosis,  such  as  laboratory  tests  and  non-
nvasive  imaging  techniques.  Laboratory  markers,  such  as
he  aspartate  aminotransferase  (AST)/alanine  aminotrans-
erase  (AST)  ratio,  AST/platelet  ratio  index  (APRI),  and
ibrosis-4  index  (FIB-4),  have  been  reported  to  be  use-
ul  to  predict  liver  ﬁbrosis.  Also,  various  ultrasound-based
echniques  have  emerged,  such  as  transient  elastography,
coustic  radiation  force  impulse  (ARFI)  imaging,  shearwave










































lDiagnostic  Performance  of  Real-Time  Elastography  in  Chroni
RTE  is  a  novel  non-invasive  ultrasound  method  for  mea-
suring  tissue  elasticity.  It  uses  ultrasound  equipment  with
an  embedded  elastography  module  and  can  be  performed
during  routine  ultrasound  examination  of  the  liver.  During
conventional  b-mode  ultrasonography,  RTE  can  measure  the
tissue  strain  response  to  mechanically  induced  deforma-
tion,  providing  qualitative  (colorimetric)  and  quantitative
readouts  (scores).  Hitachi  medical  systems  have  recently
developed  a  new  RTE  method  that  does  not  require  external
stress,  but  instead,  liver  compression  is  achieved  from  rhyth-
mic  pulsations  of  the  abdominal  aorta  and  the  heart.22--24
Published  for  the  ﬁrst  time  in  2010  by  Fujimoto  et  al.,25
the  Liver  Fibrosis  index  (LFI)  is  the  most  advanced  RTE
quantitative  score  to  evaluate  liver  ﬁbrosis  and  is  auto-
matically  calculated  by  an  image  analysis  software.  Since
then  a  limited  number  of  studies,  almost  exclusively  out-
side  of  Europe,  have  assessed  the  diagnostic  performance  of
RTE  using  the  LFI  to  predict  ﬁbrosis  in  CHC.26--29 According
to  their  results,  the  LFI  has  shown  a  very  good  diagnostic
accuracy  for  assessing  liver  ﬁbrosis,  particularly  to  pre-
dict  advanced  ﬁbrosis  (METAVIR  scoring  system  F  ≥  3)  (area
under  receiver--operator  characteristic  curve  --  AUROC  --
0.80--0.84).26--28 This  is  of  great  interest  because  in  patients
with  CHC,  the  diagnosis  of  advanced  ﬁbrosis  is  an  important
indication  for  antiviral  treatment.  As  with  other  ultrasound
techniques,  RTE  imaging  acquisition  appears  to  be  limited
by  patient  anthropometric  features.29--32 However,  to  date,
no  studies  have  determined  their  impact  on  RTE  histogram
acquisition.
The  aims  of  this  study  were,  ﬁrst,  to  compare  the  diag-
nostic  performance  of  RTE  (LFI)  versus  laboratory  tests
(AST/ALT  ratio,  APRI  and  FIB-4)  to  predict  advanced  ﬁbro-
sis  (F  ≥  3)  in  patients  with  CHC,  using  LB  as  the  reference
standard;  and,  second,  to  evaluated  the  impact  of  patient
anthropometric  features,  such  as  body  mass  index  (BMI),
waist  circumference  and  abdominal  wall  thickness,  on  RTE
histogram  acquisition.
2. Methods
This  was  a  single-centre  prospective  study.  From  November
2012  to  October  2014  (24  months),  a  total  of  37  consecu-
tive  patients  with  CHC  scheduled  for  LB  were  enrolled,  after
informed  consent.  Exclusion  criteria  comprised  the  follow-
ing:  (i)  co-infection  with  hepatitis  B  virus  or  HIV,  (ii)  history
of  autoimmune  hepatitis  or  primary  biliary  cirrhosis  and  (iii)
history  of  alcohol  abuse  (≥40  mg/day).  For  each  patient
demographic  data  (gender  and  age)  and  anthropomet-
ric  parameters  (weight,  height,  BMI,  waist  circumference
and  abdominal  wall  thickness  determined  by  ultrasound)
were  recorded.  Obesity,  overweight  and  increased  waist
circumference  were  deﬁned  according  to  WHO  criteria
(BMI  ≥  30  kg/m2,  BMI  ≥  25  kg/m2 and  waist  circumference
≥88  cm  in  men  and  ≥102  mm  in  women,  respectively).35,36
2.1.  Laboratory  tests  of  liver  ﬁbrosisBlood  tests  (including  platelet  count,  ALT  and  AST  levels)
were  drawn  within  6  months  of  the  RTE  date.  Based  on  their
results,  the  AST/ALT  ratio,  APRI  and  FIB-4  were  calculated
for  each  patient  as  follows:
n
a
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AST/ALT  ratio  =  AST  level  (UI/L)/ALT  level  (UI/L);
APRI  =  [AST  level  (UI/L)/AST  laboratory  upper  limit  of  nor-
mal  (UI/L)]/Platelet  count  (109/L);
FIB-4  =  [Age  (years)  ×  AST  level  (UI/L)]/[Platelet  count
(109/L)  ×√ALT  level  (UI/L)].
.2.  Real-time  elastography
TE  was  performed  using  Hitachi  HI-VISION  Avius  (Hitachi
loka  Medical,  Tokyo,  Japan)  and  the  EUP-L52  linear  probe
3--7  MHz,  Hitachi  Aloka  Medical),  on  the  right  lobe  of  the
iver  through  an  intercostal  space.  Liver  elasticity  was  eval-
ated  through  the  LFI  using  Hitachi  RTE  software  (Hitachi
loka  Medical),  which  performs  a  multiple  regression  anal-
sis  from  nine  ultrasound  image  features:  the  mean  of
elative  strain  value  (MEAN),  standard  deviation  of  the
elative  strain  value  (SD),  ratio  of  the  blue  area  in  the  ana-
yzed  region  (%AREA),  complexity  of  the  blue  area  (COMP),
urtosis  of  the  strain  histogram  (KURT),  skewness  of  the
train  histogram  (SKEW),  entropy  (ENT),  inverse  difference
oment  (IDM),  and  angular  second  moment  (ASM).  LFI  is
hen  automatically  calculated  according  to  the  following
ormula:
LFI  =  −0.00897  ×  MEAN  −  0.00502  ×  SD  +  0.0232  × %AREA
 0.0253  ×  COMP  + 0.775  ×  SKEW  −  0.281  ×  KURT  +  2.08
 ENT  +  3.04  ×  IDM  +  40.0  ×  ASM  −  5.54.
RTE  was  performed  by  two  independent  operators  (Bispo
 and  Marques  S,  with  3  years  and  3  months  of  experience,
espectively)  blind  to  each  other  results  and  blind  to  liver
iopsy  staging.  A  total  of  three  RTE  histograms  were  col-
ected  from  each  patient  and  the  LFI  value  was  calculated
or  each  histogram.  For  each  patient,  operators  recorded
he  histogram  acquisition,  the  mean  LFI  value  and  the  dura-
ion  of  the  complete  RTE  procedure.
.3.  Liver  biopsy
ercutaneous  ultrasound-assisted  LB  was  performed  in  the
ame  day  of  the  RTE,  using  the  same  intercostal  space  cho-
en  for  RTE  evaluation.  A  disposable  15  or  17-gauge  Menghini
eedle  was  used  (Hepaﬁx,  Braun).  All  biopsy  specimens  were
xed  in  formalin  and  embedded  in  parafﬁn  and  analyzed
y  an  expert  liver  pathologist  blind  to  the  results  of  RTE.
epatic  ﬁbrosis  was  evaluated  and  staged  according  to  the
ETAVIR  scoring  system  (F0--F4).  The  length  and  the  number
f  portal  spaces  for  each  biopsy  specimen  were  recorded.
.4.  Statistical  analysis
escriptive  statistics  were  produced  for  demographic,
nthropometric,  laboratorial,  imaging  and  histologic  data.
The  Student’s  t-test  was  used  for  comparative  analy-
is  between  groups.  Independent  variables  associated  with
nsuccessful  histogram  acquisition  were  determined  by
ogistic  regression  analysis.  The  cut-off  value  of  the  abdomi-
al  wall  thickness  signiﬁcantly  associated  with  no  histogram
cquisition  (in  logistic  regression  analysis)  was  determined.
The  intra-class  correlation  (ICC)  was  used  to  measure  the
FI  interobserver  agreement.













































Table  1  Patient  demographics,  anthropometrics  and  labo-
ratory,  imaging  and  histologic  data.
Characteristics  Patients  (n  =  37)
Gender  (male:female)  25:12
Age (years)  51  ±  8
BMI (kg/m2)  26.6  ±  4.3
Waist  circumference  (cm)  92  ±  11
Abdominal  wall  thickness  (mm)  18  ±  5
Platelet  count  (109/L)  186  ±  65
AST level  (UI/L) 81  ±  51
ALT level  (UI/L) 109  ±  74
Histogram  acquisition 32  (86%)
RTE duration  (min) 8  ±  3
Biopsy  specimen  length  (mm)  22  ±  10
Biopsy specimen  portal  spaces  15  ±  6
Fibrosis  stage
F0--1  (%) 13  (35)
F2 (%) 13  (35)





















The  diagnostic  performance  of  the  LFI,  AST/ALT  ratio,
PRI  and  FIB-4  for  predicting  advanced  ﬁbrosis  (F  ≥  3)  was
ssessed  using  the  area  under  receiver--operator  character-
stic  curve  (AUROC).  Sensitivity,  speciﬁcity,  positive  (PPV)
nd  negative  predictive  values  (NPV)  were  also  calculated
or  the  LFI,  AST/ALT  ratio,  APRI  and  FIB-4.  The  optimal
ut-off  values  for  LFI,  AST/ALT  ratio,  APRI  and  FIB-4  were
hosen  to  maximize  the  sum  of  sensitivity  and  speciﬁcity  for
dvanced  ﬁbrosis  (F  ≥  3).
Statistical  analyses  were  performed  using  SPSS  version
2.0  and  results  were  considered  statistically  signiﬁcant
hen  the  p  value  was  <0.05.
. Results
 total  of  37  patients  were  enrolled,  25  men  and  12  women
nd  the  mean  age  was  51  years  old.  The  AST/ALT  ratio,
PRI  and  FIB-4  were  calculated  for  36  patients  (one  patient
xcluded  because  of  no  recent  laboratory  evaluation).
Thirty-seven  RTE  procedures  were  performed.  Histogram
cquisition  was  successfully  achieved  in  32  patients  (86%).
MI  and  abdominal  wall  thickness  were  signiﬁcantly  higher
n  the  group  of  patients  with  no  histogram  acquisition  than
n  the  group  of  patients  with  successful  histogram  acquisi-
ion  (BMI:  32.1  kg/m2 vs  25.7  kg/m2,  respectively,  p  =  0.001;
bdominal  wall  thickness:  25.4  mm  vs  16.4  mm,  respectively,
 <  0.001).  Although  the  waist  circumference  was  higher
n  the  group  of  patients  in  whom  histogram  acquisition
ould  not  be  achieved,  the  difference  was  not  statistically
igniﬁcant  (101  cm  vs  91  cm,  respectively,  p  =  0.132).  For
verweight  and  obese  patients,  the  rate  of  unsuccessful  his-
ogram  acquisition  was  21%  (vs  7%,  p  =  0.178)  and  43%  (vs
%,  p  =  0.011),  respectively,  and  for  patients  with  increased
aist  circumference  was  29%  (vs  10%,  p  =  0.206).  By  logistic
egression,  the  cut  off  value  for  abdominal  wall  thickness
igniﬁcantly  associated  no  histogram  acquisition  was  23  mm.
or  patients  with  abdominal  wall  thickness  ≥23  mm,  the
ate  of  unsuccessful  histogram  acquisition  was  57%  (vs  3%,
 <  0.001).  By  logistic  regression  analysis,  only  abdominal
all  thickness  ≥23  mm  was  associated  with  unsuccessful  his-
ogram  acquisition  (p  =  0.018;  obesity:  p  =  0.418;  increased
aist  circumference:  p  =  0.924).
The  mean  LFI  value  was  recorded  in  all  patients  with  his-
ogram  acquisition  (n  =  32).  The  interobserver  agreement  for
he  LFI  value  was  good  (ICC  =  0.633,  p  =  0.01).
Thirty-seven  liver  biopsies  were  performed  without  any
omplication  (mean  biopsy  length:  22  mm;  mean  portal
paces  number:  15).  The  distribution  according  to  METAVIR
core  was:  F0  in  1  patient  (3%),  F1  in  12  patients  (32%),  F2
n  13  (35%),  F3  in  9  (25%)  and  F4  in  2  (5%).  The  complete





Table  2  Diagnostic  performance  of  the  LFI  and  laboratory  tests  f
AUROC  Cut-off  value  Sensitiv
LFI  0.73  2.38  100  
AST/ALT ratio  0.62  0.85  25.6  
APRI 0.79  0.73  100  
FIB-4 0.82  1.84  100  F4 (%) 2  (5)
RTE  (LFI)  showed  a very  good  diagnostic  performance  for
redicting  advanced  ﬁbrosis  (F  ≥  3)  in  chronic  hepatitis  C,
ith  excellent  sensitivity  and  NPV  (both  100%).  These  results
ere  comparable  to  those  obtained  from  laboratory  tests
AST/ALT  ratio,  APRI  and  FIB-4).  The  diagnostic  performance
f  the  LFI  and  laboratory  tests  for  predicting  advanced  ﬁbro-
is  (F  ≥  3)  is  presented  in  Table  2  and  Fig.  1.
. Discussion
n  recent  years,  there  has  been  an  increasing  interest  in  non-
nvasive  assessment  of  liver  ﬁbrosis  in  clinical  practice,  using
aboratory  tests  and  imaging  techniques,  as  alternatives
o  LB.  RTE  is  a non-invasive  ultrasound  method  for  the
easurement  of  tissue  elasticity  with  proven  accuracy  in
valuating  liver  ﬁbrosis,  especially  in  CHC.  It  is  particularly
seful  to  predict  advanced  ﬁbrosis  (F  ≥  3),  one  of  the  main
ndications  for  antiviral  therapy  in  patients  with  CHC.26--34
ery  few  studies  have  assessed  the  diagnostic  performance
f  the  LFI  to  evaluate  liver  ﬁbrosis  in  CHC  patients.  Kim
t  al.,26 compared  the  diagnostic  accuracy  of  the  LFI,  APRI
nd  FIB-4  to  predict  advanced  ﬁbrosis  (F  ≥  3)  and  cirrhosis
F  =  4)  in  chronic  viral  hepatitis  B  and  C.  They  concluded  that
nly  the  LFI  had  a  signiﬁcant  power  to  estimate  advanced
brosis  (F  ≥  3)  and  cirrhosis  (F  =  4)  (vs  APRI  and  FIB-4).  They
lso  reported  that  the  LFI  was  more  accurate  to  predict
dvanced  ﬁbrosis  (F  ≥  3)  in  CHC  than  in  chronic  hepatitis  B
or  predicting  advanced  ﬁbrosis  (F  ≥  3).
ity  (%)  Speciﬁcity  (%)  PPV  (%)  NPV  (%)
65.2  52.9  100
76.0  50.0  79.2
48.0  45.8  100
64.0  55.0  100






























































treating adults infected with Hepatitis C virus. Hepatology.Figure  1  ROC  of  the  LFI,  AST/ALT  ratio,  APRI  and  FIB-4  for
the predicting  advanced  ﬁbrosis  (F  ≥  3).
patients  (AUROC  0.80  vs  0.64).  Another  study,  from  Tamaki
et  al.,27 revealed  not  only  that  the  LFI  was  a  very  good
method  to  predict  advanced  ﬁbrosis  (F  ≥  3)  in  CHC,  but  also
that  its  diagnostic  accuracy  was  superior  to  laboratory  tests
(AUROC:  LFI  0.84,  platelet  count  0.82,  APRI  0.76,  and  FIB-
4  0.80).  Similar  results  were  obtained  by  Ferraioli  et  al.,28
showing  that  the  LFI  was  useful  to  predict  advanced  ﬁbrosis
(F  ≥  3)  in  CHC  (AUROC  0.80).  The  only  portuguese  study  ever
published  to  date  concerning  the  use  of  RTE  in  CHC  for  liver
ﬁbrosis  assessment  was  performed  by  Magalhães  et  al.37 This
study  included  patients  with  chronic  viral  hepatitis  B  and
C  (5  patients  with  CHC  and  10  patients  with  chronic  hep-
atitis  B)  and  showed  that  LFI  had  a  moderate  correlation
with  METAVIR  histologic  scoring  system  (Spearman’s  0.56,
p  =  0.03).
In  our  prospective  study,  RTE  showed  a  very  good  diagnos-
tic  performance  for  predicting  advanced  ﬁbrosis  (F  ≥  3)  in
patients  with  CHC.  Using  the  optimal  cut-off  value  of  2.38,
the  AUROC  for  the  LFI  was  0.73.  These  results  were  sim-
ilar  or  better  than  those  of  the  laboratory  tests.  In  fact,
LFI  diagnostic  performance  was  superior  to  AST/ALT  ratio
(AUROC  0.73  vs  0.62).  Comparing  to  APRI  (AUROC  0.79)  and
FIB-4  (AUROC  0.82),  the  LFI  showed  an  identical  diagnostic
accuracy  with  excellent  sensitivity  and  NPV  (both  100%).  The
results  obtained  in  our  study  were  similar  to  those  published
in  the  literature.
Transient  elastography,  commonly  known  as  Fibroscan,
has  been  widely  used  to  evaluate  liver  stiffness  and  is  estab-
lished  in  clinical  practice  to  assess  liver  ﬁbrosis.  However,
transient  elastography  cannot  be  performed  in  patients  with
narrow  intercostal  spaces,  ascites  or  severe  obesity  and
is  inﬂuenced  by  the  presence  of  liver  inﬂammation  and
steatosis.24 Unlike  TE,  RTE  is  performed  during  conventional
b-mode  ultrasonography,  therefore,  allowing  identiﬁcation
of  a  suitable  location  for  liver  ﬁbrosis  assessment.  Still,  RTE
histogram  acquisition  may  be  limited  by  narrow  intercostal
spaces,  poor  ultrasound  tissue  penetration  and  poor  car-
diac  and  aortic  movement.24 Poor  ultrasound  penetrationpatitis  C  17
s  usually  reported  in  patients  with  thick  abdominal  wall
r  obesity.29--32 According  to  the  few  studies  that  did  not
xclude  patients  with  obesity  or  with  a  thick  abdominal  wall,
he  RTE  histogram  acquisition  rate  ranges  from  73.5%  to
4.9%.29,30 In  our  study,  all  patients  were  included,  despite
heir  BMI  and  abdominal  wall  thickness  (51%  overweigh  and
9%  obese  patients  and  19%  patients  with  increased  waist
ircumference).  RTE  histogram  acquisition  was  achieved
n  86%  of  patients.  In  the  group  of  patients  with  unsuc-
essful  histogram  acquisition,  the  BMI  and  abdominal  wall
hickness  were  signiﬁcantly  higher  than  in  the  group  of
atients  with  successful  histogram  acquisition  (p  =  0.001  and
 <  0.001,  respectively).  Also  in  patients  with  obesity  or  with
bdominal  wall  thickness  ≥23  mm  the  rate  of  unsuccess-
ul  histogram  acquisition  was  signiﬁcantly  reduced  (p  =  0.011
nd  p  <  0.001).  However,  by  logistic  regression  analysis,  the
nly  anthropometric  feature  associated  with  unsuccessful
istogram  acquisition  was  abdominal  wall  thickness  ≥23  mm
p  =  0.018).  To  our  knowledge,  no  other  study  has  evaluated
he  impact  of  patient  anthropometric  features  on  RTE  his-
ogram  acquisition.
Our  study  had  some  limitations.  The  number  of  patients,
articularly  with  advanced  ﬁbrosis,  was  small.  Also,  a  sec-
nd  liver  pathologist  should  have  evaluated  each  LB  to
inimize  bias  related  to  interobserver  variability.  However,
his  prospective  single  centre  study  supports  the  promising
esults  of  RTE  in  the  recent  literature.
.  Conclusion
n  conclusion,  RTE  is  a  promising  non-invasive,  reproducible
nd  easy  to  use  technique  to  assess  liver  ﬁbrosis  in  CHC.
he  LFI  calculated  by  RTE  shows  a  very  good  diagnostic  per-
ormance  to  predict  advanced  ﬁbrosis  (F  ≥  3)  in  CHC,  with
imilar  results  to  laboratory  tests.
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